Mark Nedelman, MS, MBA, is President of Ekam Imaging, Inc, a nonclinical neuroimaging contract research organization (CRO) specializing in awake animal imaging providing drug discovery services to the biomedical industries. Ekam is a spin-out of the Center for Translational Neuroimaging at Northeastern University. Mark started his drug development career in the nuclear medicine research laboratory at Massachusetts General Hospital in Boston from 1983-87. From there, he was recruited to start and head the Preclinical Pharmacology efforts at Centocor, Inc. in Malvern, PA where he was an Associate Director from 1987-1996 playing key roles in leading the preclinical development and approval of a number first-in-class drugs. In 1996 he joined a leading CRO to set strategy and develop new specialty services unique (at the time) to the contract industry. He held a number of leadership positions within Charles River Laboratories including being its Senior Director of Pharmacology, Surgery and Toxicology from 2000-2003 and then General Manager of a multi-site business unit, which he established, Interventional and Surgical Services from 2003-2006. From 2006 until he was asked to assume leadership of Ekam in 2010, he was a drug development consultant to a number of biotechnology start-ups as well as being Senior Director of Business Development at SelectX Pharmaceuticals. His accomplishments over 25 years in the industry includes one patent, over 100 abstracts and invited presentations, more than 35 original, peer-reviewed publications and three book chapters covering the fields of cardiology, oncology, imaging, infectious diseases and inflammation. Mark has a B.S. and M.S. in Biology from the University of Cincinnati and a M.B.A. from Northeastern University.